Monoclonal antibodies for the treatment of Ebola virus disease. (1st November 2016)

• Record Type: Journal Article
• Authors: Moekotte, A. L.; Huson, M. A. M.; van der Ende, A. J.; Agnandji, S.T.; Huizenga, E.; Goorhuis, A.; Grobusch, M. P.
• Is Part Of: Expert opinion on investigational drugs. Volume 25:Number 11(2016:Nov.)
• Page Start: 1325
• Page End: 1335
• Publication Date: 2016-11-01
• Subjects: Ebolavirus disease -- therapy -- monoclonal antibodies -- MB-003 -- ZMAb -- ZMappTM -- MIL-77E -- mAb114; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2016.1240785
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction : To date, the management of patients with suspected or confirmed Ebolavirus disease (EVD) depends on quarantine, symptomatic management and supportive care, as there are no approved vaccines or treatments available for human use. However, accelerated by the recent large outbreak in West Africa, significant progress has been made towards vaccine development but also towards specific treatment with convalescent plasma and monoclonal antibodies. Areas covered : We describe recent developments in monoclonal antibody treatment for EVD, encompassing mAb114 and the MB-003, ZMAb, ZMapp™ and MIL-77E cocktails. Expert opinion : Preventive measures, are, and will remain essential to curb EVD outbreaks; even more so with vaccine development progressing. However, research for treatment options must not be neglected. Small-scale animal and individual human case studies show that monoclonal antibodies (mAbs) can be effective for EVD treatment; thus justifying exploration in clinical trials. Potential limitations are that high doses may be needed to yield clinical efficacy; epitope mutations might reduce efficacy; and constant evolution of (outbreak-specific) mAb mixtures might be required. Interim advice based on the clinical experience to date is that treatment of patients with mAbs is sensible, provided those could be made available in the necessary amounts in time.